Apple And Zimmer Biomet To Study Patient Experience With Joint Replacement Surgery

16 Oct 2018

The study will evaluate Zimmer Biomet's mymobility app on the Apple Watch and iPhone to guide patients undergoing knee or hip surgery through both pre- and post-op care.

MT1810_Smart Watch_518918716_1200.jpg — • Source: shutterstock.com

Zimmer Biomet Holdings Inc. is working with Apple Inc. to study how its new mymobility app for the Apple Watch and iPhone can help patients navigate the knee- and hip-replacement surgery, from pre-op preparation through post-op recovery.

The move fits with an accelerating push for device companies to enhance digital and data analytics offerings linked to conventional...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Medicare Tricuspid Regurgitation Coverage Decision Big Win For Abbott

15 Jul 2025

• By Brian Bossetta

Medicare beneficiaries with tricuspid regurgitation will now have access to an innovative treatment from Abbott that offers a minimally invasive alternative to open-heart surgery.

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

09 Jul 2025

• By Brian Bossetta

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

Novel Pathway For Combined Drug/IVD Trials Wins Backing Of EU Nations

03 Jul 2025

• By Vibha Sharma

Broad participation by EU member states in a new pilot to test a unified procedure for evaluating applications for combined drug and IVD studies shows they recognize its value, says Monique Al, vice-chair of the Clinical Trials Coordination Group.

‘Be Quick, But Don’t Hurry’: Dexcom CEO Talks CGM Market Success

02 Jul 2025

• By Marion Webb

Dexcom’s CEO Kevin Sayer discusses this fall’s planned launch of the 15-day G7 CGM, downplays Abbott’s dual-sensor while focusing on development of multi-analyte G8, making OTC Stelo app more “consumerish” for Europeans, and more.